Genmab A/S (NASDAQ:GMAB) Stock Position Increased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 26.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 218,078 shares of the company's stock after buying an additional 45,376 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Genmab A/S were worth $5,480,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. SG Americas Securities LLC grew its stake in Genmab A/S by 360.5% in the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company's stock worth $882,000 after purchasing an additional 23,094 shares in the last quarter. Harding Loevner LP increased its holdings in shares of Genmab A/S by 2.7% in the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company's stock valued at $97,569,000 after acquiring an additional 85,665 shares during the last quarter. Capital International Investors raised its position in shares of Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Aigen Investment Management LP acquired a new stake in shares of Genmab A/S during the 4th quarter valued at approximately $1,143,000. Finally, Choreo LLC bought a new position in Genmab A/S during the second quarter worth $776,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Price Performance

Shares of GMAB traded down $0.32 during trading hours on Monday, reaching $26.58. 531,863 shares of the company's stock traded hands, compared to its average volume of 572,277. Genmab A/S has a twelve month low of $24.53 and a twelve month high of $37.97. The business's fifty day simple moving average is $27.27 and its two-hundred day simple moving average is $28.06. The firm has a market capitalization of $17.58 billion, a price-to-earnings ratio of 22.15, a P/E/G ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The company had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. On average, equities research analysts expect that Genmab A/S will post 1.27 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. BTIG Research boosted their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a report on Friday. Morgan Stanley reaffirmed an "equal weight" rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Finally, Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a report on Monday, July 15th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.